PE20020486A1 - Compuestos triciclicos como inhibidores de la farnesil proteino transferasa - Google Patents
Compuestos triciclicos como inhibidores de la farnesil proteino transferasaInfo
- Publication number
- PE20020486A1 PE20020486A1 PE2001000865A PE2001000865A PE20020486A1 PE 20020486 A1 PE20020486 A1 PE 20020486A1 PE 2001000865 A PE2001000865 A PE 2001000865A PE 2001000865 A PE2001000865 A PE 2001000865A PE 20020486 A1 PE20020486 A1 PE 20020486A1
- Authority
- PE
- Peru
- Prior art keywords
- united
- compounds
- link
- farnesil
- tricyclic compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229950008696 farnesil Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 abstract 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 abstract 1
- -1 CHLORMETINE Chemical compound 0.000 abstract 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 230000003325 follicular Effects 0.000 abstract 1
- 229960001101 ifosfamide Drugs 0.000 abstract 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 abstract 1
- 229960000952 pipobroman Drugs 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 abstract 1
- 229960001055 uracil mustard Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS TRICICLICOS DE FORMULA I DONDE UNO DE a, b, c, d ES N, N+O-; EL RESTO SON C SUSTITUIDOS CON R1 O R2; SI X Y C11 ESTAN UNIDOS POR ENLACE SIMPLE, X ES N, CH; SI ENTRE X Y C11 ESTAN UNIDOS POR DOBLE ENLACE X ES C; SI C5 Y C6 ESTA UNIDOS POR ENLACE DOBLE A Y B NO SON H; SI C5 Y C6 ESTAN UNIDOS POR ENLACE SIMPLE UNO DE A Y B ES H, O A Y B SON R9, R9C0R9, (CH2)pC(R9)-OR9a, ENTRE OTROS; p ES 0-4; R1 Y R2 SON H, HALO, CF3, OR10, S(O)tR15, ENTRE OTROS; t ES 0-2; R3 Y R4 SON H, R1, R2; R5, R6, R7, SON H, CF3, COR10, ALQUILO, ARILO, ENTRE OTROS; R9 ES HETEROARILO, ARILALCOXI, HETEROCICLOALCOXI, ENTRE OTROS; R9a ARILO, ARILALQUILO. R10 ES H, ALQUILO, ARILO, ARILALQUILO; R15 ES ALQUILO, ARILO. LOS COMPUESTOS SE PUEDEN UTILIZAR CON QUIMIOTERAPICOS O RADIACION COMO MOSTAZA DE URACILO, CLORMETINA, CICLOFOSFAMIDA, IFOSFAMIDA, PIPOBROMAN, COLCHICINA, PACLITAXEL, EPOLTIONA, GEMCITABINA, ENTRE OTROS. LOS COMPUESTOS INHIBEN A CELULAS QUE EXPRESAN ONCOGEN DE RAS ACTIVADO POR INHIBICION DE LA FARNESIL TRANSFERASA Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE CANCER DE PULMON, PANCREATICO, COLON, LEUCEMIA MIELOIDE, FOLICULAR TIROIDEO, VEJIGA GLIOMA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22918300P | 2000-08-30 | 2000-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020486A1 true PE20020486A1 (es) | 2002-06-14 |
Family
ID=22860141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000865A PE20020486A1 (es) | 2000-08-30 | 2001-08-28 | Compuestos triciclicos como inhibidores de la farnesil proteino transferasa |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20020198216A1 (es) |
| EP (1) | EP1313725B1 (es) |
| JP (1) | JP2004513885A (es) |
| KR (1) | KR20030034161A (es) |
| CN (1) | CN100384837C (es) |
| AR (1) | AR033680A1 (es) |
| AT (1) | ATE359281T1 (es) |
| AU (2) | AU8845101A (es) |
| BR (1) | BR0113675A (es) |
| CA (1) | CA2420673A1 (es) |
| CO (1) | CO5640109A2 (es) |
| DE (1) | DE60127846T2 (es) |
| EC (1) | ECSP034494A (es) |
| ES (1) | ES2284686T3 (es) |
| HK (1) | HK1054548B (es) |
| HU (1) | HUP0302942A3 (es) |
| IL (1) | IL154528A0 (es) |
| MX (1) | MXPA03001849A (es) |
| NO (1) | NO20030918L (es) |
| NZ (1) | NZ524246A (es) |
| PE (1) | PE20020486A1 (es) |
| PL (1) | PL361103A1 (es) |
| RU (1) | RU2293734C9 (es) |
| SK (1) | SK2292003A3 (es) |
| TW (1) | TWI268280B (es) |
| WO (1) | WO2002018368A1 (es) |
| ZA (1) | ZA200301545B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| BRPI0207961B8 (pt) | 2001-03-14 | 2021-05-25 | Bristol Myers Squibb Co | uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. |
| EP1435959A2 (en) * | 2001-10-09 | 2004-07-14 | University of Cincinnati | Inhibitors of the egf receptor for the treatment of thyroid cancer |
| WO2003047697A2 (en) * | 2001-11-30 | 2003-06-12 | Schering Corporation | Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
| EP1453513A1 (en) * | 2001-12-03 | 2004-09-08 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| EP1613308A4 (en) * | 2003-03-27 | 2008-02-20 | Lankenau Inst Medical Res | CANCER TREATMENT METHODS |
| WO2005000230A2 (en) * | 2003-06-05 | 2005-01-06 | Charles Achkar | Methods of treating hyperproliferative cell disorders |
| BRPI0411250A (pt) * | 2003-06-09 | 2006-08-29 | Samuel Waksal | método de inibição de receptor tirosina cinase com um antagonista extracelular e um antagonista intracellular |
| ES2235611B2 (es) * | 2003-07-25 | 2006-07-16 | Universidade De Santiago De Compostela | Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas. |
| RU2006106768A (ru) | 2003-08-07 | 2007-09-20 | Шеринг Корпорейшн (US) | Новые ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты |
| US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
| WO2006069208A2 (en) * | 2004-12-21 | 2006-06-29 | Schering Corporation | Novel farnesyl protein transferase inhibitors as antitumor agents |
| RU2361587C1 (ru) * | 2008-02-14 | 2009-07-20 | Михаил Владимирович Кутушов | Лекарственное средство для лечения онкологических заболеваний |
| EP2313091A4 (en) * | 2008-07-14 | 2012-04-04 | Univ Kingston | PHARMACEUTICAL COMPOSITIONS WITH RET-HEMMERN AND METHOD FOR THE TREATMENT OF CANCER |
| CN114025751A (zh) * | 2019-06-28 | 2022-02-08 | 安徽荣航生物科技发展有限责任公司 | 用于治疗乙型肝炎病毒感染的组合物和方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| IE68935B1 (en) * | 1990-06-22 | 1996-07-24 | Schering Corp | Bis-benzo or benzopyrido cyclohepta piperidene piperidylidene and piperazine compounds compositions and methods of use |
| US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| PE92098A1 (es) * | 1996-07-31 | 1998-12-31 | Schering Corp | N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo |
| US6071907A (en) * | 1996-09-13 | 2000-06-06 | Schering Corporation | Tricyclic compounds useful as FPT inhibitors |
| US5925648A (en) * | 1997-07-29 | 1999-07-20 | Schering Corporation | Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase |
| IL143409A0 (en) * | 1998-12-18 | 2002-04-21 | Schering Corp | Farnesyl protein transferase inhibitors |
-
2001
- 2001-08-27 AR ARP010104082A patent/AR033680A1/es unknown
- 2001-08-28 EP EP01968188A patent/EP1313725B1/en not_active Expired - Lifetime
- 2001-08-28 ES ES01968188T patent/ES2284686T3/es not_active Expired - Lifetime
- 2001-08-28 RU RU2003108865/04A patent/RU2293734C9/ru not_active IP Right Cessation
- 2001-08-28 KR KR10-2003-7003012A patent/KR20030034161A/ko not_active Ceased
- 2001-08-28 WO PCT/US2001/026792 patent/WO2002018368A1/en not_active Ceased
- 2001-08-28 NZ NZ524246A patent/NZ524246A/en unknown
- 2001-08-28 MX MXPA03001849A patent/MXPA03001849A/es active IP Right Grant
- 2001-08-28 HU HU0302942A patent/HUP0302942A3/hu unknown
- 2001-08-28 JP JP2002523486A patent/JP2004513885A/ja active Pending
- 2001-08-28 IL IL15452801A patent/IL154528A0/xx unknown
- 2001-08-28 CN CNB01818121XA patent/CN100384837C/zh not_active Expired - Fee Related
- 2001-08-28 SK SK229-2003A patent/SK2292003A3/sk not_active Application Discontinuation
- 2001-08-28 PE PE2001000865A patent/PE20020486A1/es not_active Application Discontinuation
- 2001-08-28 BR BR0113675-5A patent/BR0113675A/pt not_active IP Right Cessation
- 2001-08-28 DE DE60127846T patent/DE60127846T2/de not_active Expired - Fee Related
- 2001-08-28 PL PL01361103A patent/PL361103A1/xx unknown
- 2001-08-28 TW TW090121201A patent/TWI268280B/zh active
- 2001-08-28 AT AT01968188T patent/ATE359281T1/de not_active IP Right Cessation
- 2001-08-28 AU AU8845101A patent/AU8845101A/xx active Pending
- 2001-08-28 CA CA002420673A patent/CA2420673A1/en not_active Abandoned
- 2001-08-28 US US09/940,811 patent/US20020198216A1/en not_active Abandoned
- 2001-08-28 AU AU2001288451A patent/AU2001288451C1/en not_active Ceased
- 2001-08-28 HK HK03105016.6A patent/HK1054548B/en not_active IP Right Cessation
-
2003
- 2003-02-25 ZA ZA200301549A patent/ZA200301545B/xx unknown
- 2003-02-26 EC EC2003004494A patent/ECSP034494A/es unknown
- 2003-02-27 NO NO20030918A patent/NO20030918L/no not_active Application Discontinuation
- 2003-02-27 CO CO03017118A patent/CO5640109A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020486A1 (es) | Compuestos triciclicos como inhibidores de la farnesil proteino transferasa | |
| CY1106125T1 (el) | Ενωσεις πυρρολινης υποκατεστημενες με ινδαζολυλιο ως αναστολεις κινασης | |
| ES2132373T3 (es) | Benzocicloheptenos, benzoxepinas y benzotiepinas. | |
| AR022323A1 (es) | Complejo del inhibidor de ras-farnesiltransferasa y sulfobutileter-7-beta-ciclodextrina o 2-hidroxipropil-beta-ciclodextrina y composiciones formuladas condicho complejo | |
| CO5180568A1 (es) | Compuestos farmaceuticos, especialmente mutilinas, composiciones farmaceuticas que los contienen | |
| PE57399A1 (es) | Sulfamidas utiles como inhibidores de metaloproteasas | |
| DE69914893D1 (de) | Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase | |
| MXPA05010638A (es) | Aditivo para cemento. | |
| DE69401658D1 (de) | Verwendung von deoxygalactonojirimycin derivaten zu hemmung der glycolipid synthese | |
| AR029773A1 (es) | Un metodo para inhibir la polimerizacion prematura de monomeros etilenicamente insaturados y una composicion de un monomero etilenicamente insaturado preparada con el mismo | |
| ATE524522T1 (de) | Xanthen-farbstoffe | |
| ES2044013T3 (es) | Compuesto mesomorfico, una composicion de cristal liquido que contiene el compuesto y un dispositivo de cristal liquido que utiliza la composicion. | |
| CO4900071A1 (es) | Derivados de pirido [4´, 3´:4,5] tieno (2,3- d) pirimidina sustituidos en posicion 3 | |
| ES2174781T3 (es) | Articulo coextruido de resina de policarbonato. | |
| ATE251145T1 (de) | Amino- und hydroxy-substituierte triphenyl-s- triazine als stabilisatoren | |
| CO5690604A2 (es) | Derivados de [6,7-dihidro-5h-imidazo[1.2-alfa]imidazol-3- sulfonilamino]-propionamida | |
| ATE247660T1 (de) | Furopyridinderivate und ihre therapeutische verwendung | |
| ES2059864T3 (es) | Compuesto mesomorfico, composicion de cristal liquido que contiene el mismo y dispositivo de cristal liquido que lo utiliza. | |
| PE20001342A1 (es) | Compuestos triciclicos como inhibidores de farnesil transferasa | |
| TW200704653A (en) | Ultraviolet absorbing polymer for high light resistant recording materials | |
| CY1107287T1 (el) | Χρηση της ερυθροποιητινης, καθως και παραγωγων αυτης για τη θεραπεια σχιζοφρενειων και συναφων ψυχωσεων | |
| ES2066187T3 (es) | Compuestos de fosforo. | |
| EP0870503A4 (en) | INHIBITORS OF VICTORY TUMOR METASTASIS | |
| ES475588A1 (es) | Procedimiento para la obtencion de derivados del acido inde-no -2,1-b- tiofen-2-oxamico | |
| PE20030197A1 (es) | Derivados de pirrol heteroarilo-substituidos como inhibidores de la produccion de citosinas inflamatorias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |